LDL-C Lowering Market, Germany

Visibility — think of it as response coverage. It measures the percentage of unique AI responses that mention a brand or molecule at least once.

Share of Voice — think of it as mention frequency. It measures a brand or molecule's share of all tracked mentions, including repeated mentions within the same response.

The two answer different questions. Visibility shows how broadly a brand is covered across responses. Share of Voice shows how much of the conversation it captures through mentions, including multiple mentions within the same response. A brand can therefore have high Visibility but lower Share of Voice — or the reverse.

What was not measured

This is a Visibility & Share of Voice benchmark across AI models. It measures how broadly an asset is covered across AI answers and how frequently it is mentioned by name. It does not show how AI models talk about the pharma asset or whether that representation aligns with the brand strategy.

It does not show whether a therapy is described accurately, which attributes it is associated with, why a competitor is represented differently, or what could be changed. A therapy that appears in almost every answer may still be represented in ways that do not support the manufacturer's commercial objectives.

A full Theralexis assessment goes much further — beyond the visibility metrics typically associated with SEO and GEO tools. We uncover how AI systems talk about your brand, whether that representation aligns with your strategy, which sources and channels are shaping it, and what content actions can strengthen your competitive position.